Literature DB >> 27417650

18F-FNDP for PET Imaging of Soluble Epoxide Hydrolase.

Andrew G Horti1, Yuchuan Wang2, Il Minn2, Xi Lan3, Jian Wang3, Raymond C Koehler3, Nabil J Alkayed4, Robert F Dannals2, Martin G Pomper1.   

Abstract

Soluble epoxide hydrolase (sEH) is a bifunctional enzyme located within cytosol and peroxisomes that converts epoxides to the corresponding diols and hydrolyzes phosphate monoesters. It serves to inactivate epoxyeicosatrienoic acids (EETs), which are generated in the brain to couple neuronal activity and cerebral blood flow in normal and pathologic states. Altered regulation of sEH was observed previously in various neuropathologic disorders including vascular dementia and stroke. Inhibitors of sEH are pursued as agents to mitigate neuronal damage after stroke. We developed N-(3,3-diphenylpropyl)-6-18F-fluoronicotinamide (18F-FNDP), which proved highly specific for imaging of sEH in the mouse and nonhuman primate brain with PET.
METHODS: 18F-FNDP was synthesized from the corresponding bromo precursor. sEH inhibitory activity of 18F-FNDP was measured using an sEH inhibitor screening assay kit. Biodistribution was undertaken in CD-1 mice. Binding specificity was assayed in CD-1 and sEH knock-out mice and Papio anubis (baboon) through pretreatment with an sEH inhibitor to block sEH binding. Dynamic PET imaging with arterial blood sampling was performed in 3 baboons, with regional tracer binding quantified using distribution volume. The metabolism of 18F-FNDP in baboons was assessed using high-performance liquid chromatography.
RESULTS: 18F-FNDP (inhibition binding affinity constant, 1.73 nM) was prepared in 1 step in a radiochemical yield of 14% ± 7%, specific radioactivity in the range of 888-3,774 GBq/μmol, and a radiochemical purity greater than 99% using an automatic radiosynthesis module. The time of preparation was about 75 min. In CD-1 mice, regional uptake followed the pattern of striatum > cortex > hippocampus > cerebellum, consistent with the known brain distribution of sEH, with 5.2% injected dose per gram of tissue at peak uptake. Blockade of 80%-90% was demonstrated in all brain regions. Minimal radiotracer uptake was present in sEH knock-out mice. PET baboon brain distribution paralleled that seen in mouse, with a marked blockade (95%) noted in all regions indicating sEH-mediated uptake of 18F-FNDP. Two hydrophilic metabolites were identified, with 20% parent compound present at 90 min after injection in baboon plasma.
CONCLUSION: 18F-FNDP can be synthesized in suitable radiochemical yield and high specific radioactivity and purity. In vivo imaging experiments demonstrated that 18F-FNDP targeted sEH in murine and nonhuman primate brain specifically. 18F-FNDP is a promising PET radiotracer likely to be useful for understanding the role of sEH in a variety of conditions affecting the central nervous system.
© 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Entities:  

Keywords:  baboon; epoxyeicosatrienoic acid; molecular neuroimaging; positron emission tomography; soluble epoxide hydrolase; stroke; vascular cognitive impairment

Mesh:

Substances:

Year:  2016        PMID: 27417650      PMCID: PMC5095511          DOI: 10.2967/jnumed.116.173245

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  22 in total

1.  An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension.

Authors:  John D Imig; Xueying Zhao; Constantine Z Zaharis; Jeffrey J Olearczyk; David M Pollock; John W Newman; In-Hae Kim; Takaho Watanabe; Bruce D Hammock
Journal:  Hypertension       Date:  2005-09-12       Impact factor: 10.190

2.  Cerebrovascular pathology and dementia in autopsied Honolulu-Asia Aging Study participants.

Authors:  Lon White; Helen Petrovitch; John Hardman; James Nelson; Daron G Davis; G Webster Ross; Kamal Masaki; Lenore Launer; William R Markesbery
Journal:  Ann N Y Acad Sci       Date:  2002-11       Impact factor: 5.691

3.  Soluble Epoxide Hydrolase Deficiency or Inhibition Attenuates MPTP-Induced Parkinsonism.

Authors:  Xiaocui Qin; Qiaoqi Wu; Lifang Lin; Aimin Sun; Shuhu Liu; Xiaowen Li; Xiong Cao; Tianming Gao; Pengcheng Luo; Xinhong Zhu; Xuemin Wang
Journal:  Mol Neurobiol       Date:  2014-08-17       Impact factor: 5.590

4.  Role of soluble epoxide hydrolase in age-related vascular cognitive decline.

Authors:  Jonathan W Nelson; Jennifer M Young; Rohan N Borkar; Randy L Woltjer; Joseph F Quinn; Lisa C Silbert; Marjorie R Grafe; Nabil J Alkayed
Journal:  Prostaglandins Other Lipid Mediat       Date:  2014-09-30       Impact factor: 3.072

Review 5.  PET imaging in ischemic cerebrovascular disease: current status and future directions.

Authors:  Wolf-Dieter Heiss
Journal:  Neurosci Bull       Date:  2014-08-19       Impact factor: 5.203

6.  Soluble Epoxide Hydrolase Inhibition: Targeting Multiple Mechanisms of Ischemic Brain Injury with a Single Agent.

Authors:  Jeffrey J Iliff; Nabil J Alkayed
Journal:  Future Neurol       Date:  2009-03-01

7.  Discovery of (-)-7-methyl-2-exo-[3'-(6-[18F]fluoropyridin-2-yl)-5'-pyridinyl]-7-azabicyclo[2.2.1]heptane, a radiolabeled antagonist for cerebral nicotinic acetylcholine receptor (alpha4beta2-nAChR) with optimal positron emission tomography imaging properties.

Authors:  Yongjun Gao; Hiroto Kuwabara; Charles E Spivak; Yingxian Xiao; Kenneth Kellar; Hayden T Ravert; Anil Kumar; Mohab Alexander; John Hilton; Dean F Wong; Robert F Dannals; Andrew G Horti
Journal:  J Med Chem       Date:  2008-07-08       Impact factor: 7.446

8.  Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase.

Authors:  Anne B Eldrup; Fariba Soleymanzadeh; Steven J Taylor; Ingo Muegge; Neil A Farrow; David Joseph; Keith McKellop; Chuk C Man; Alison Kukulka; Stéphane De Lombaert
Journal:  J Med Chem       Date:  2009-10-08       Impact factor: 7.446

9.  Distribution of soluble and microsomal epoxide hydrolase in the mouse brain and its contribution to cerebral epoxyeicosatrienoic acid metabolism.

Authors:  A Marowsky; J Burgener; J R Falck; J-M Fritschy; M Arand
Journal:  Neuroscience       Date:  2009-06-18       Impact factor: 3.590

Review 10.  Diagnostic accuracy of (18)F amyloid PET tracers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.

Authors:  Elizabeth Morris; Anastasia Chalkidou; Alexander Hammers; Janet Peacock; Jennifer Summers; Stephen Keevil
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-28       Impact factor: 9.236

View more
  10 in total

Review 1.  Reconceptualization of translocator protein as a biomarker of neuroinflammation in psychiatry.

Authors:  T Notter; J M Coughlin; A Sawa; U Meyer
Journal:  Mol Psychiatry       Date:  2017-12-05       Impact factor: 15.992

2.  An optimized radiosynthesis of [18 F]FNDP, a positron emission tomography radiotracer for imaging soluble epoxide hydrolase (sEH).

Authors:  Babak Behnam Azad; Daniel P Holt; Hayden T Ravert; Andrew G Horti; Robert F Dannals
Journal:  J Labelled Comp Radiopharm       Date:  2018-05-07       Impact factor: 1.921

3.  First-in-human neuroimaging of soluble epoxide hydrolase using [18F]FNDP PET.

Authors:  Jennifer M Coughlin; Stephanie Slania; Yong Du; Laura K Shinehouse; Mary Katherine Brosnan; Babak Behnam Azad; Daniel P Holt; Hong Fan; Wojciech G Lesniak; Il Minn; Steven P Rowe; Robert F Dannals; Andrew G Horti; Martin G Pomper
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-13       Impact factor: 9.236

Review 4.  The Repertoire of Small-Molecule PET Probes for Neuroinflammation Imaging: Challenges and Opportunities beyond TSPO.

Authors:  Zhen Chen; Ahmed Haider; Jiahui Chen; Zhiwei Xiao; Luca Gobbi; Michael Honer; Uwe Grether; Steven E Arnold; Lee Josephson; Steven H Liang
Journal:  J Med Chem       Date:  2021-12-14       Impact factor: 8.039

Review 5.  Imaging inflammation and its resolution in health and disease: current status, clinical needs, challenges, and opportunities.

Authors:  Christina H Liu; Natalie D Abrams; Danielle M Carrick; Preethi Chander; Johanna Dwyer; Michelle R J Hamlet; Andrei L Kindzelski; Mercy PrabhuDas; Shang-Yi Anne Tsai; Merriline M Vedamony; Chiayeng Wang; Pushpa Tandon
Journal:  FASEB J       Date:  2019-10-09       Impact factor: 5.834

6.  Blockade of soluble epoxide hydrolase attenuates post-ischemic neuronal hyperexcitation and confers resilience against stroke with TrkB activation.

Authors:  Li-Hsin Chang; Hui-Ching Lin; Shiang-Suo Huang; I-Chih Chen; Kai-Wen Chu; Chun-Lien Chih; Yao-Wen Liang; Yi-Chung Lee; You-Yin Chen; Yi-Hsuan Lee; I-Hui Lee
Journal:  Sci Rep       Date:  2018-01-08       Impact factor: 4.379

Review 7.  Molecular Imaging of Hydrolytic Enzymes Using PET and SPECT.

Authors:  Brian P Rempel; Eric W Price; Christopher P Phenix
Journal:  Mol Imaging       Date:  2017 Jan-Dec       Impact factor: 4.488

8.  PET imaging of soluble epoxide hydrolase in non-human primate brain with [18F]FNDP.

Authors:  Yong Du; Il Minn; Catherine Foss; Wojciech G Lesniak; Feng Hu; Robert F Dannals; Martin G Pomper; Andrew G Horti
Journal:  EJNMMI Res       Date:  2020-06-22       Impact factor: 3.138

Review 9.  PET imaging of the neurovascular interface in cerebrovascular disease.

Authors:  Nicholas R Evans; Jason M Tarkin; John R Buscombe; Hugh S Markus; James H F Rudd; Elizabeth A Warburton
Journal:  Nat Rev Neurol       Date:  2017-10-06       Impact factor: 42.937

10.  Soluble Epoxide Hydrolase Blockade after Stroke Onset Protects Normal but Not Diabetic Mice.

Authors:  Catherine M Davis; Wenri H Zhang; Elyse M Allen; Thierno M Bah; Robert E Shangraw; Nabil J Alkayed
Journal:  Int J Mol Sci       Date:  2021-05-21       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.